Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

This study has been completed.
Becton, Dickinson and Company
Information provided by:
Brooke Army Medical Center Identifier:
First received: February 9, 2006
Last updated: February 13, 2006
Last verified: December 2005
The main purpose of this study is to determine if applying mupirocin into soldiers noses who are colonized with methicillin-resistant Staphylococcus aureus (MRSA) will reduce infections in them and their cohort of fellow soldiers.

Condition Intervention
Community-Acquired MRSA Infections
Drug: Mupirocin (drug)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus Infection in Soldiers: a Controlled Trial

Resource links provided by NLM:

Further study details as provided by Brooke Army Medical Center:

Primary Outcome Measures:
  • Soft tissue infections in subjects who received the study medication and soft tissue infections in the study cohorts.

Secondary Outcome Measures:
  • Changes in S. aureus carriage rates (including MRSA).

Estimated Enrollment: 3000
Study Start Date: January 2005
Estimated Study Completion Date: December 2005
Detailed Description:
Community-acquired MRSA infections are increasingly common in the community and in particular among certain groups of which soldiers are one. Many researchers and clinicians have postulated that one method to prevent infections is to selectively eradicate CA-MRSA in those who are colonized with the pathogen. The two main purposes of the study are: to determine if selective CA-MRSA eradication in subjects reduces infections in the CA-MRSA colonized individual; and to determine if selective CA-MRSA eradication in subjects reduces infections in the study cohort. Other information concerning CA-MRSA includes: prevalence, risk factors, and virulence data. The population will be soldiers enrolled in the combat medic training class at Ft. Sam Houston. We will enroll approximately 3000 soldiers over a two year period. After informed written consent, we will culture their anterior nares nares and administer questionnaires at the beginning and at the end of the study, following them prospectively for infections. The follow-up period will be 16 weeks. For those with CA-MRSA in their nares, they will be randomized (by cohort) to receive either 5 days of mupirocin or placebo.

Ages Eligible for Study:   17 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:Soldiers enrolled into the combat medic course at Ft. Sam Houston, TX.

Exclusion Criteria: Allergy to mupirocin.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00289588

United States, Texas
Brooke Army Medical Center
Ft. Sam Houston, Texas, United States, 78234
Sponsors and Collaborators
Brooke Army Medical Center
Becton, Dickinson and Company
Principal Investigator: Michael W Ellis, MD Brooke Army Medical Center
  More Information

Publications: Identifier: NCT00289588     History of Changes
Other Study ID Numbers: C.2004.163
Study First Received: February 9, 2006
Last Updated: February 13, 2006

Keywords provided by Brooke Army Medical Center:
Methicillin-resistant Staphylococcus aureus
Staphylococcus aureus

Additional relevant MeSH terms:
Communicable Diseases
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Skin Diseases, Infectious
Connective Tissue Diseases
Pathologic Processes
Hair Diseases
Skin Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 22, 2017